Caribou Biosciences Inc. (NASDAQ:CRBU) shares fell 35.07% to $0.74 in after-hours trading Tuesday after the company announced it is exploring strategic alternatives and plans to discontinue its two cell therapy programs.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company.

Strategic Alternatives, Program Discontinuation

Caribou’s Board of Directors approved initiating a process to evaluate strategic alternatives, including a potential merger, acquisition or other strategic transaction involving the company and/or its assets, according to a press release. Wedbush Securities Inc. has been engaged as the company’s exclusive financial advisor for the process. Caribou said it has not set a timeline for completing the review and does not plan to provide further updates until the board approves a course of action or the process concludes.

In conjunction with the announcement, Caribou plans to discontinue further development of vispa-cel and CB-011, its two allogeneic CAR-T cell therapy programs, and implement a substantial workforce reduction expected to be mostly complete in the fourth quarter of 2026.

“This is an extraordinarily difficult decision, particularly because it is in no way a reflection of our belief that vispa-cel and CB-011 have the potential to benefit patients,” said Rachel Haurwitz, president and CEO of Caribou. She said the current financing environment for allogeneic CAR-T cell therapies had made it “increasingly challenging to secure the capital necessary to responsibly advance these programs.”

As of June 30, 2026, Caribou had $113.8 million in cash, cash equivalents and marketable securities.

Trading Metrics, Technical Analysis

Caribou Biosciences has a market capitalization of approximately $124.75 million.

Over the past year, Caribou Biosciences shares have fallen 53.29%.

The stock has traded between a 52-week high of $3.53 and a 52-week low of $1.13.

Benzinga’s Edge Stock Rankings show a negative price trend across short-, medium- and long-term time frames.

Price Action: In the regular session, Caribou Biosciences shares fell 4.62% to close at $1.14 on Tuesday.

Photo: Who is Danny / Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.